Julia Piasecki

Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma

Paula Rodríguez‐Otero, Sikander Ailawadhi, Bertrand Arnulf et al. · New England Journal of Medicine · 2023 · 705 citations · Full text

Medicine, Immunology, Oncology +17

Apo2L/TRAIL and the Death Receptor 5 Agonist Antibody AMG 655 Cooperate to Promote Receptor Clustering and Antitumor Activity

Jonathan D. Graves, Jennifer J. Kordich, Tzu-Hsuan Huang et al. · Cancer Cell · 2014 · 155 citations · Full text

Life Sciences, Oncology, Pharmacology +17

JCARH125, Anti-BCMA CAR T-cell Therapy for Relapsed/Refractory Multiple Myeloma: Initial Proof of Concept Results from a Phase 1/2 Multicenter Study (EVOLVE)

Sham Mailankody, Myo Htut, Kelvin P. Lee et al. · Blood · 2018 · 124 citations

Medicine, Hematology, Oncology +16

Local Delivery of OncoVEXmGM-CSF Generates Systemic Antitumor Immune Responses Enhanced by Cytotoxic T-Lymphocyte–Associated Protein Blockade

Achim K. Moesta, Keegan S. Cooke, Julia Piasecki et al. · Clinical Cancer Research · 2017 · 105 citations

Life Sciences, Immunology, Oncology +17

Ide-cel vs standard regimens in triple-class–exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses

Sikander Ailawadhi, Bertrand Arnulf, Krina K. Patel et al. · Blood · 2024 · 63 citations · Full text

Medicine, Oncology, Immunotherapy +13